Skip to main content
Erschienen in: AIDS and Behavior 2/2014

01.02.2014 | Substantive Review

Motivators to Participation in Actual HIV Vaccine Trials

verfasst von: Shayesta Dhalla, Gary Poole

Erschienen in: AIDS and Behavior | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

An examination of actual HIV vaccine trials can contribute to an understanding of motivators for participation in these studies. Analysis of these motivators reveals that they can be categorized as social and personal benefits. Social benefits are generally altruistic, whereas personal benefits are psychological, physical, and financial. In this systematic review, the authors performed a literature search for actual preventive HIV vaccine trials reporting motivators to participation. Of studies conducted in the Organization for Economic Co-operation and Development (OECD) countries, the authors retrieved 12 studies reporting on social benefits and seven reporting on personal benefits. From the non-OECD countries, nine studies reported on social benefits and eight studies on personal benefits. Social benefits were most frequently described on macroscopic, altruistic levels. Personal benefits were most frequently psychological in nature. Rates of participation were compared between the OECD and the non-OECD countries. Knowledge of actual motivators in specific countries and regions can help target recruitment in various types of actual HIV vaccine trials.
Literatur
1.
Zurück zum Zitat Dhalla S, Poole G. Motivators of enrolment in HIV vaccine trials: a review of HIV vaccine preparedness studies. AIDS Care. 2011;23(11):1430–47.PubMedCrossRef Dhalla S, Poole G. Motivators of enrolment in HIV vaccine trials: a review of HIV vaccine preparedness studies. AIDS Care. 2011;23(11):1430–47.PubMedCrossRef
2.
Zurück zum Zitat Poole G. Using psychological principles to narrow the intention-behavior gap and increase participation in HIV vaccine trials. Curr HIV Res. 2012;10(6):552–6.PubMedCrossRef Poole G. Using psychological principles to narrow the intention-behavior gap and increase participation in HIV vaccine trials. Curr HIV Res. 2012;10(6):552–6.PubMedCrossRef
3.
Zurück zum Zitat Becker MH. The health belief model and sick role behavior. Health Educ Monogr. 1974;2:409–19. Becker MH. The health belief model and sick role behavior. Health Educ Monogr. 1974;2:409–19.
4.
Zurück zum Zitat Luzi AM, Gallo P, Colucci A, Marcotullio S, Bellino S, Longo O, et al. Communication, recruitment and enrolment in the preventative and therapeutic phase I clinical trial against HIV/AIDS based on the recombinant HIV-1 Tat protein. AIDS Care. 2011;23(8):939–46.PubMedCrossRef Luzi AM, Gallo P, Colucci A, Marcotullio S, Bellino S, Longo O, et al. Communication, recruitment and enrolment in the preventative and therapeutic phase I clinical trial against HIV/AIDS based on the recombinant HIV-1 Tat protein. AIDS Care. 2011;23(8):939–46.PubMedCrossRef
5.
Zurück zum Zitat Tarimo EA, Thorson A, Kohi TW, Bakari M, Sandstrom E, Mhalu F, et al. A qualitative evaluation of volunteers’ experiences in a phase I/II HIV vaccine trial in Tanzania. BMC Infect Dis. 2011;11:283.PubMedCentralPubMedCrossRef Tarimo EA, Thorson A, Kohi TW, Bakari M, Sandstrom E, Mhalu F, et al. A qualitative evaluation of volunteers’ experiences in a phase I/II HIV vaccine trial in Tanzania. BMC Infect Dis. 2011;11:283.PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Chesney MA, Chambers DB, Kahn JO. Risk behavior for HIV infection in participants in preventive HIV vaccine trials: a cautionary note. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16(4):266–71.PubMedCrossRef Chesney MA, Chambers DB, Kahn JO. Risk behavior for HIV infection in participants in preventive HIV vaccine trials: a cautionary note. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16(4):266–71.PubMedCrossRef
7.
Zurück zum Zitat Buchbinder SP, Metch B, Holte SE, Scheer S, Coletti A, Vittinghoff E. Determinants of enrollment in a preventive HIV vaccine trial: hypothetical versus actual willingness and barriers to participation. J Acquir Immune Defic Syndr. 2004;36(1):604–12.PubMedCrossRef Buchbinder SP, Metch B, Holte SE, Scheer S, Coletti A, Vittinghoff E. Determinants of enrollment in a preventive HIV vaccine trial: hypothetical versus actual willingness and barriers to participation. J Acquir Immune Defic Syndr. 2004;36(1):604–12.PubMedCrossRef
9.
Zurück zum Zitat Newman PA, Daley A, Halpenny R, Loutfy M. Community heroes or “high-risk” pariahs? Reasons for declining to enroll in an HIV vaccine trial. Vaccine. 2008;26(8):1091–7.PubMedCrossRef Newman PA, Daley A, Halpenny R, Loutfy M. Community heroes or “high-risk” pariahs? Reasons for declining to enroll in an HIV vaccine trial. Vaccine. 2008;26(8):1091–7.PubMedCrossRef
10.
Zurück zum Zitat Harro CD, Judson FN, Gorse GJ, Mayer KH, Kostman JR, Brown SJ, et al. Recruitment and baseline epidemiologic profile of participants in the first phase 3 HIV vaccine efficacy trial. J Acquir Immune Defic Syndr. 2004;37(3):1385–92.PubMedCrossRef Harro CD, Judson FN, Gorse GJ, Mayer KH, Kostman JR, Brown SJ, et al. Recruitment and baseline epidemiologic profile of participants in the first phase 3 HIV vaccine efficacy trial. J Acquir Immune Defic Syndr. 2004;37(3):1385–92.PubMedCrossRef
11.
Zurück zum Zitat Colfax G, Buchbinder S, Vamshidar G, Celum C, McKirnan D, Neidig J, et al. Motivations for participating in an HIV vaccine efficacy trial. J Acquir Immune Defic Syndr. 2005;39(3):359–64.PubMedCrossRef Colfax G, Buchbinder S, Vamshidar G, Celum C, McKirnan D, Neidig J, et al. Motivations for participating in an HIV vaccine efficacy trial. J Acquir Immune Defic Syndr. 2005;39(3):359–64.PubMedCrossRef
12.
Zurück zum Zitat Vanichseni S, Tappero JW, Pitisuttithum P, Kitayaporn D, Mastro TD, Vimutisunthorn E, et al. Recruitment, screening and characteristics of injection drug users participating in the AIDSVAX B/E HIV vaccine trial, Bangkok, Thailand. AIDS. 2004;18(2):311–6.PubMedCrossRef Vanichseni S, Tappero JW, Pitisuttithum P, Kitayaporn D, Mastro TD, Vimutisunthorn E, et al. Recruitment, screening and characteristics of injection drug users participating in the AIDSVAX B/E HIV vaccine trial, Bangkok, Thailand. AIDS. 2004;18(2):311–6.PubMedCrossRef
13.
Zurück zum Zitat Pitisuttithum P, Choopanya K, Rerk-Ngnam S. HIV-vaccine research and development in Thailand: evolution and challenges. Vaccine. 2010;28(Suppl 2):B45–9.PubMedCrossRef Pitisuttithum P, Choopanya K, Rerk-Ngnam S. HIV-vaccine research and development in Thailand: evolution and challenges. Vaccine. 2010;28(Suppl 2):B45–9.PubMedCrossRef
14.
Zurück zum Zitat Voytek CD, Jones KT, Metzger DS. Selectively willing and conditionally able: HIV vaccine trial participation among women at “high risk” of HIV infection. Vaccine. 2011;29(36):6130–5.PubMedCentralPubMedCrossRef Voytek CD, Jones KT, Metzger DS. Selectively willing and conditionally able: HIV vaccine trial participation among women at “high risk” of HIV infection. Vaccine. 2011;29(36):6130–5.PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Johnson MO. Belief of vaccine receipt in HIV vaccine trials: further cautions. J Acquir Immune Defic Syndr. 1999;21(5):413–6.PubMed Johnson MO. Belief of vaccine receipt in HIV vaccine trials: further cautions. J Acquir Immune Defic Syndr. 1999;21(5):413–6.PubMed
16.
Zurück zum Zitat Thapinta D, Jenkins RA, Morgan PA, et al. Recruiting volunteers for a multisite phase I/II HIV preventive vaccine trial in Thailand. J Acquir Immune Defic Syndr. 2002;30(5):503–13.PubMedCrossRef Thapinta D, Jenkins RA, Morgan PA, et al. Recruiting volunteers for a multisite phase I/II HIV preventive vaccine trial in Thailand. J Acquir Immune Defic Syndr. 2002;30(5):503–13.PubMedCrossRef
17.
Zurück zum Zitat Jenkins RA, Thapinta D, Morgan PA, et al. Behavioral and social issues among volunteers in a preventive HIV vaccine trial in Thailand. J Acquir Immune Defic Syndr. 2005;40(5):592–9.PubMedCrossRef Jenkins RA, Thapinta D, Morgan PA, et al. Behavioral and social issues among volunteers in a preventive HIV vaccine trial in Thailand. J Acquir Immune Defic Syndr. 2005;40(5):592–9.PubMedCrossRef
18.
Zurück zum Zitat Lucero MC, Diaz-Brito V, Murillo BT, Carretero SC, Sala M, Casadesus C, et al. Reasons for not participating in a phase 1 preventive HIV vaccine study in a resource-rich country. AIDS Patient Care STDs. 2012;26(7):379–82.PubMed Lucero MC, Diaz-Brito V, Murillo BT, Carretero SC, Sala M, Casadesus C, et al. Reasons for not participating in a phase 1 preventive HIV vaccine study in a resource-rich country. AIDS Patient Care STDs. 2012;26(7):379–82.PubMed
19.
Zurück zum Zitat Jenkins RA, Temoshok LR, Virochsiri K. Incentives and disincentives to participate in prophylactic HIV vaccine research. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;9(1):36–42.PubMedCrossRef Jenkins RA, Temoshok LR, Virochsiri K. Incentives and disincentives to participate in prophylactic HIV vaccine research. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;9(1):36–42.PubMedCrossRef
20.
Zurück zum Zitat Crumbo CL, Rybczyk GK, Wagner LJ. Characteristics of volunteer participants in phase I HIV vaccine trials. J Assoc Nurses AIDS Care. 1997;8(5):59–65.PubMedCrossRef Crumbo CL, Rybczyk GK, Wagner LJ. Characteristics of volunteer participants in phase I HIV vaccine trials. J Assoc Nurses AIDS Care. 1997;8(5):59–65.PubMedCrossRef
21.
Zurück zum Zitat Belshe RB, Stevens C, Gorse GJ, Buchbinder S, Weinhold K, Sheppard H, et al. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. J Infect Dis. 2001;183(9):1343–52.PubMedCrossRef Belshe RB, Stevens C, Gorse GJ, Buchbinder S, Weinhold K, Sheppard H, et al. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. J Infect Dis. 2001;183(9):1343–52.PubMedCrossRef
22.
Zurück zum Zitat Gray K, Legg K, Sharp A, Mackie N, Olarinde F, De Souza C, et al. Participation in two phase II prophylactic HIV vaccine trials in the UK. Vaccine. 2008;26(23):2919–24.PubMedCrossRef Gray K, Legg K, Sharp A, Mackie N, Olarinde F, De Souza C, et al. Participation in two phase II prophylactic HIV vaccine trials in the UK. Vaccine. 2008;26(23):2919–24.PubMedCrossRef
23.
Zurück zum Zitat Phanuphak P, Teeratakulpixarn S, Sarangbin S, et al. International clinical trials of HIV vaccines: I. Phase I trial of an HIV-1 synthetic peptide vaccine in Bangkok, Thailand. Asian Pac J Allergy Immunol. 1997;15(1):41–8.PubMed Phanuphak P, Teeratakulpixarn S, Sarangbin S, et al. International clinical trials of HIV vaccines: I. Phase I trial of an HIV-1 synthetic peptide vaccine in Bangkok, Thailand. Asian Pac J Allergy Immunol. 1997;15(1):41–8.PubMed
24.
Zurück zum Zitat Jenkins RA, Chinaworapong S, Morgan PA, Ruangyuttikarn C, Sontirat A, Chiu J, et al. Motivation, recruitment, and screening of volunteers for a phase I/II HIV preventive vaccine trial in Thailand. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(2):171–7.PubMedCrossRef Jenkins RA, Chinaworapong S, Morgan PA, Ruangyuttikarn C, Sontirat A, Chiu J, et al. Motivation, recruitment, and screening of volunteers for a phase I/II HIV preventive vaccine trial in Thailand. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(2):171–7.PubMedCrossRef
25.
Zurück zum Zitat Cleghorn F, Pape JW, Schechter M, Bartholomew C, Sanchez J, Jack N, et al. Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120. J Acquir Immune Defic Syndr. 2007;46(2):222–30.PubMedCrossRef Cleghorn F, Pape JW, Schechter M, Bartholomew C, Sanchez J, Jack N, et al. Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120. J Acquir Immune Defic Syndr. 2007;46(2):222–30.PubMedCrossRef
26.
Zurück zum Zitat Bakari M, Aboud S, Nilsson C, et al. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. Vaccine. 2011;29(46):8417–28.PubMedCrossRef Bakari M, Aboud S, Nilsson C, et al. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. Vaccine. 2011;29(46):8417–28.PubMedCrossRef
Metadaten
Titel
Motivators to Participation in Actual HIV Vaccine Trials
verfasst von
Shayesta Dhalla
Gary Poole
Publikationsdatum
01.02.2014
Verlag
Springer US
Erschienen in
AIDS and Behavior / Ausgabe 2/2014
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-013-0519-8

Weitere Artikel der Ausgabe 2/2014

AIDS and Behavior 2/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

VHF-Ablation nützt wohl nur bei reduzierter Auswurfleistung

02.05.2024 Ablationstherapie Nachrichten

Ob die Katheterablation von Vorhofflimmern bei Patienten mit Herzinsuffizienz die Komplikationsraten senkt, scheint davon abzuhängen, ob die Auswurfleistung erhalten ist oder nicht. Das legen die Ergebnisse einer Metaanalyse nahe.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.